louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03439969: A 8-month Study on the Use of Intra-oral Camera and Text Messages on Gingivitis Control
Official title: The Whole is Greater Than the Sum of Its Parts. "A 8-month Randomised Controlled Trial on the Use of Intra-oral Camera and Text Messages on Gingivitis Control"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Behavior and Behavior Mechanisms
Gingivitis
Keywords: Gingivitis
SMS
Text messages
Behavior change
HAPA
Dental Hygiene
Lead sponsor: University of Lisbon
Sponsor class: OTHER
First posted: 2018-02-20
Enrollment: 233
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To investigate the effects of using an intra-oral camera (IOC) during supportive periodontal therapy, and oral hygiene mobile text messages (SMS) between appointments on clinical, behavioral and psychological parameters of patients with gingivitis.

Detailed description: Dental hygiene behaviours are of paramount importance for controlling gingival health. There is evidence on the use of IOC and of text messages in boosting motivation, sustainability and clinical efficacy of dental hygiene behaviors. Orchestrating these two technologies is expected to create a coaction effect which could improve behavior change interventions, but the effectiveness of such strategy needs to be inspected.

Eligibility criteria: Inclusion Criteria:

Gingivitis BOMP \> 0.5 20 teeth (minimum 5 per quadrant) \> 18 years old

Exclusion Criteria:

periodontitis (pockets \>3), smoking, orthodontics, pregnancy removable partial dentures

Primary outcomes:
measure: Change from BOMP (Bleeding on Marginal Probing) at 4 & 8 months
timeFrame: Baseline, 4 months & 8 months
Secondary outcomes:
measure: HAPA (Health Action Process Approach) behavioral variables questionnaire.
timeFrame: Baseline, 4 & 8 months.
measure: SMS (Short Messages Service) text messages opinion questionnaire
timeFrame: At 4 months.
measure: Intra Oral Camera opinion questionnaire
timeFrame: At 4 and 8 months.
measure: Self-report Dental Hygiene Behaviors questionnaire.
timeFrame: Baseline, 4 and 8 months.
Other outcomes:
Locations:
Study officials:
References:
citation: Godinho CA, Alvarez MJ, Lima ML, Schwarzer R. Health messages to promote fruit and vegetable consumption at different stages: A match-mismatch design. Psychol Health. 2015;30(12):1410-32. doi: 10.1080/08870446.2015.1054827. Epub 2015 Jul 24.
Clinical trial NCT04886869: Caffeine and the Autonomic Nervous System
Official title: Impact of Caffeine Consumption on Markers of the Autonomic Nervous System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Autonomic Nervous System Imbalance
Lead sponsor: LMU Klinikum
Sponsor class: OTHER
First posted: 2021-05-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: Caffeine consumption has been linked to dysfunction of the autonomic nervous system. In this study the investigators analyze the effects of caffeine containing drinks (including energy drinks and coffee) on ECG based parameters of the autonomic nervous system.


Eligibility criteria: Inclusion Criteria:

* healthy individuals
* \> 18 years

Exclusion Criteria:

* known cardiovascular disease
* other diseases which may influence the autonomic nervous system
* medication which may influence the autonomic nervous system
* prior caffeine consumption (\<24 hours)

Primary outcomes:
measure: Heart rate (HR)
timeFrame: 2 hours
Secondary outcomes:
measure: Periodic repolarization dynamics (PRD)
timeFrame: 2 hours
Other outcomes:
Locations:
city: Munich
country: Germany
facility: University Hospital Munich (LMU Klinikum)
Study officials:
References:
citation: Schuttler D, Rudi WS, Bauer A, Hamm W, Brunner S. Impact of energy drink versus coffee consumption on periodic repolarization dynamics: an interventional study. Eur J Nutr. 2022 Aug;61(5):2847-2851. doi: 10.1007/s00394-022-02853-8. Epub 2022 Mar 10.
Clinical trial NCT05382169: Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders
Official title: Prevalence of Mast Cell Activation Syndrome in Patients With Ehlers Danlos Hypermobile Syndrome With Digestive Disorders
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ehlers Danlos Hypermobile Syndrome
Keywords: Genetic disease
Collagen abnormality
Nausea
Heartburn
Ehlers Danlos hypermobile syndrome
Mast cell activation syndrome (MCAS)
Allergology
Lead sponsor: Lille Catholic University
Sponsor class: OTHER
First posted: 2022-05-19
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with EDSh with digestive disorders

Brief summary: The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.


Eligibility criteria: Inclusion Criteria:

* with hypermobile Ehlers Danlos syndrome
* with digestive disorders
* 14 years of age or older (minimum age for the MOS-SF 36 questionnaire)
* able to answer the questionnaires
* whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned
* who do not object to the use of their health data for research purposes

Additional criteria for minors :

- No objection to the use of health data for research purposes by parents/guardians

Exclusion Criteria:

* under guardianship or curatorship
* having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last two months, according to the following thresholds :

  * Desloratadine (\>5 mg/jour)
  * Bilastine (\>20 mg/jour)
  * Cetirizine (\>20 mg/jour)
  * Ebastine (\>10 mg/jour)
  * Fexofenadine (\>150 mg/jour)
  * Levocetirizine (\>5 mg/jour)
  * Loratadine (\>10 mg/jour)
  * Exocetiridine (5 mg/jour)
  * Mizolastine (\>10 mg/jour)
  * Rupatadine (\>10 mg/jour)
  * Polaramine (\>10 mg/jour)
  * Oxomemazine (\>2 mg/jour)
  * Hydroxyzine (\>25 mg/jour)
  * Doxylamine (\>15 mg/jour)
  * Cimetidine (\>200 mg/jour)
* Patients deprived of liberty, pregnant or nursing women

Primary outcomes:
measure: Prevalence of mast cell activation syndrome in patients with hypermobile Ehlers Danlos syndrome with digestive disorders
timeFrame: 2 months
Secondary outcomes:
measure: Frequency of the symptoms after treatment with anti-histamines
timeFrame: 2 months
measure: Medical Outcome Study Short-Form 36 (MOS SF-36 ) survey after antihistamine treatment
timeFrame: 2 months
measure: Frequency of consumption of analgesics
timeFrame: 2 months
measure: Frequency of intolerance according to particular food consumption
timeFrame: 2 months
Other outcomes:
Locations:
city: Lille
country: France
facility: Saint-Vincent-de-Paul hospital
state: Nord
Study officials:
affiliation: Lille Catholic University
name: Juliette CARON, Md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00600769: Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Official title: Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Nontuberculous Mycobacteria
Mycobacterium Avium Complex
Keywords: MAC
NTM
Lead sponsor: The University of Texas Health Science Center at Tyler
Sponsor class: OTHER
Collaborators: name: Abbott
First posted: 2008-01-25
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

Detailed description: Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history

Eligibility criteria: Inclusion Criteria:

* Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
* Age 18 years and older

Exclusion Criteria:

* History of macrolide allergy
* Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
* Children less than 18 years of age
* If a menstruating female, not pregnant and on adequate birth control

Primary outcomes:
measure: Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures
timeFrame: 6 months
Secondary outcomes:
measure: Microbiological cultures
timeFrame: 1yr
Other outcomes:
Locations:
city: Tyler
country: United States
facility: The University of Texas Health Science Center at Tyler
state: Texas
Study officials:
affiliation: UTHSCT
name: Richard J Wallace, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00446069: A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
Official title: A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Cancer
Lead sponsor: Egalet Ltd
Sponsor class: INDUSTRY
First posted: 2007-03-12
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.


Eligibility criteria: Inclusion Criteria:

* The patient has stable strong opioid use equipotent to 30-240 mg oral morphine sulphate daily for a minimum of 2 weeks prior to entering the run-in phase.
* The patient has opioid-sensitive pain caused by active cancer.
* The patient is aged minimum 18 years.

Exclusion Criteria:

* The patient has a life expectancy less than 2 months.
* The patient has received chemotherapy or radiation therapy less than 4 weeks prior to entering run-in phase
* Patients with medical conditions contraindicating morphine treatment
* The patient has hepatic disease or impaired kidney function
* The patient is taking monoamine oxidase inhibitors (MAOIs) or has taken a MAOI within two weeks prior to entering baseline.
* The patient is taking other opioid agonists or antagonists, zidovudine or cimetidine.

Primary outcomes:
measure: Use of rescue medication
timeFrame: 2 weeks treatment
Secondary outcomes:
measure: Pain intensity
timeFrame: 2 weeks treatment
Other outcomes:
Locations:
city: Kaunas
country: Lithuania
facility: Site 51
city: Vilnius
country: Lithuania
facility: Site 50
city: Bielsko-Biaia
country: Poland
facility: Site 63
city: Bydgoszcz
country: Poland
facility: Site 60
city: Poznań
country: Poland
facility: Site 62
city: Warszawa
country: Poland
facility: Site 61
city: Wrocław
country: Poland
facility: Site 64
city: Włocławek
country: Poland
facility: Site 65
Study officials:
affiliation: Egalet A/S
name: Christine Andersen, MSc Pharm
role: STUDY_DIRECTOR
References:
Clinical trial NCT05893069: Oxandrolone Multiligament Knee
Official title: Ability of Oral Oxandrolone to Aid in Rehabilitation and Outcomes of Multiligament Knee Reconstructions: A Double-Blind, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Ligament Tear Knee
Keywords: Oxandrolone
Testosterone
Anabolic Steroid
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2023-06-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is about healing after a rmultiligament knee reconstruction procedure. We hope to learn if a biologic medication: Oxandrolone, a synthetic derivative of the human hormone Testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.


Eligibility criteria: Inclusion Criteria:

• Patients with MRI proven multiligament knee injury scheduled to undergo multiligament knee reconstruction

Exclusion Criteria:

* Patients with prior ipsilateral knee surgery
* Untreated diabetes mellitus
* Pituitary tumor
* Rheumatoid Arthritis
* Uncontrolled hypertension
* Congestive Heart Failure
* Myocardial Infarction within the past 6 months
* End-stage renal disease
* Liver enzymes two times the normal value
* DVT within the past 6 months
* Disorder of the coagulation system
* Currently taking anticoagulation
* Prior or current use of anabolic steroids
* Chromosomal disorders
* Prostate cancer
* Breast cancer
* Hypercalcemia
* Patients with COPD not responsive to bronchodilators
* Patients with known liver disease
* Patients at risk for liver tumors
* Severe hyperlipidemia
* Patients taking medications that interfere with testosterone production or function, including but not limited to 5α-reductase inhibitors, acetaminophen (Tylenol, others), cholesterol lowering

Primary outcomes:
measure: lean body mass
timeFrame: Change from baseline at 52 weeks
measure: body fat percentage
timeFrame: Change from baseline at 52 weeksf
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Keck School of Medicine of the University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: George Hatch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06923969: Balneotherapy; As a Complementary Way of Maintaining Cardiac Health
Official title: Can Balneotherpy be Effective in Prevention and Maintenance of Cardiac Health As a Complementary Intervention in Adult-Elderly Persons
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis
Keywords: Balneotherapy
Echocardiography
Wellness
Heart
Lead sponsor: Bursa City Hospital
Sponsor class: OTHER_GOV
First posted: 2025-04-11
Enrollment: 44
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 44 patients who were consulted to cardiology outpatient clinic before and after the Spa therapy were retrospectively investigated.

Brief summary: Balneotherapy has been defined as the use of thermal, mineral waters for medical purposes. To highlight its possible effects on cardiac health, echocardiographic parameters were retrospectively analysed before and after the treatment in adult-elderly osteoarthritis patients.

Detailed description: Thermal therapies are mostly preferred by adult-elderly patients, and it is highly probable that known or hidden cardiovascular disease prevalences are higher among these patients. Therefore, a cardiovascular examination may be required both before and after the intervention.

To find out effects of bath therapy on echocardiographic parameters, patients who were consulted to cardiology outpatient clinic before and after the Spa therapy were retrospectively investigated.

Eligibility criteria: Inclusion Criterias:

* Having balneotherapy sessions 5 days a week for total of three weeks
* Having detailed echocardiography records

Exclusion Criterias:

* Individuals who do not have detailed echocardiography records,
* Having history of major surgery,
* cerebrovascular accident,
* malignancy,
* liver or renal failure,
* immunodeficiency,
* acute/chronic infection,
* psychiatric disorders were exluded.

Primary outcomes:
measure: Number of patients with spa therapy related cardiac changes as assessed by Echocardiography
timeFrame: Baseline and 3 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Bursa Military Hospital, 1. Murat Caddesi Osmangazi
state: Nilüfer
Study officials:
References:
Clinical trial NCT02930369: Effects of Different Area of Internal Limiting Membrane Peeling (ILM) Peeling on Anatomical Outcomes in Macular Hole Surgery
Official title: A Randomized, Comparative, Prospective Study of Anatomical Outcomes With Different Internal Limiting Membrane Peeling Area in Surgery for Idiopathic Macular Hole
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Macular Hole
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2016-10-12
Enrollment: 128
Sex: ALL
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effects of two different internal limiting membrane (ILM) peeling area on anatomical closure outcomes after macular hole surgery measured by optical coherence tomography (OCT).


Eligibility criteria: Inclusion Criteria:

* patients with IMH
* patients signed the informed consent form (ICF)
* patients with course of IMH less than 3 years

Exclusion Criteria:

* patients with hyper myopia
* patients with traumatic macular hole
* accompanied or secondary of other fundus disease
* open or reopen after receiving MH surgery
* patients with retinal detachment
* received vitrectomy due to other diseases
* glaucoma cannot be controled by medication
* patients with other retinal or choroidal disease that may affect VA
* poor patients compliance
* poor condition that cannot undertake the surgery
* dioptric media opacities which make it difficult to exam fundus or measure on OCT

Primary outcomes:
measure: Anatomical closure grades in OCT
timeFrame: 1 year
Secondary outcomes:
measure: Change of anatomical closure grades in OCT
timeFrame: 3 months, 6 months, 1 year
measure: Change from baseline in BCVA (best corrected visual acuity)
timeFrame: 3 months, 6 months, 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Peking University People's Hospital
name: Mingwei Zhao, M.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT04872569: Pilot Testing A Pregnancy Decision Making Tool for Women With Spinal Cord Injury (SCI)
Official title: Pilot Testing A Pregnancy Decision Making Tool for Women With Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Cord Injuries
Pregnancy Related
Keywords: Decision tool
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: The Craig H. Neilsen Foundation
First posted: 2021-05-04
Enrollment: 23
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this project is to pilot test a decision-making tool that is tailored for women with SCI to support them in the decision-making process. Pilot testing focuses on feasibility and preliminary efficacy.

Detailed description: The purpose of this project is to pilot test a decision-making tool that is tailored for women with SCI to support them in the decision-making process. Pilot testing focuses on feasibility and preliminary efficacy.

Eligibility criteria: Inclusion Criteria:

* Spinal cord injury (traumatic or non-traumatic)
* Need for assistance with daily life activities and/or personal care; women with mild, moderate or severe severity will be eligible
* actively planning or in the process of making a decision about whether or not to get pregnant in the near future

Exclusion Criteria:

- No plans for getting pregnant

Primary outcomes:
measure: Final Decisional Conflict Scale Score - Values Clarity Sub-scale
timeFrame: 12 weeks
measure: Final Decisional Conflict Scale Score - Support Sub-scale
timeFrame: 12 weeks
measure: Final Decisional Conflict Scale Score - Uncertainty Sub-scale
timeFrame: 12 weeks
measure: Final Readiness to Make a Choice in Stage of Decision-Making Scale
timeFrame: 12 weeks
Secondary outcomes:
measure: Feasibility - Acceptability
timeFrame: 12 weeks
measure: Feasibility - Demand
timeFrame: 12 weeks
measure: Feasibility - Ease of Use
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Claire Kalpakjian, PhD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00823069: Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose
Official title: A Randomized, Double-Blind Study Comparing Safety and Tolerability of Perlane® With and Without Addition of 0.3% Lidocaine HCL During Correction of Nasolabial Folds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nasolabial Folds
Keywords: Correction of Nasolabial Folds
Lead sponsor: Medicis Global Service Corporation
Sponsor class: INDUSTRY
Collaborators: name: Q-Med Scandinavia, Inc.
First posted: 2009-01-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety study that compares Perlane to Perlane with Lidocaine while correcting wrinkles in the area around your nose.

Detailed description: This is a split-face design. All 60 subjects receive Perlane on one side of their face, and Perlane-L on the other. Subjects and the investigator is blinded to which side of face receives which product. These are one time injections.

Eligibility criteria: Inclusion Criteria:

* Same Wrinkle Severity Rating Scale score at both Nasolabial Folds (either both Moderate \[3\] or both Severe \[4\])

Exclusion Criteria:

* Active or chronic skin disease, inflammation or related conditions, near or on the Nasolabial Folds
* Subjects who had undergone procedures based on active dermal response (e.g., laser or chemical peeling procedures) within 6 months prior to study entry
* Use of any facial tissue augmenting therapy with non-permanent filler or aesthetic facial surgical therapy within 9 months prior to study entry
* Permanent implant placed in the Nasolabial Fold area

Primary outcomes:
measure: Treatment Difference in VAS (Perlane Side - Perlane-L Side) With Difference in VAS >= 10 mm
timeFrame: After Injection on Day of Treatment
Secondary outcomes:
measure: Number of Subjects Showing Wrinkle Improvement at Day 14
timeFrame: 14 days after treatment when compared to baseline
Other outcomes:
Locations:
city: Coral Gables
country: United States
state: Florida
city: Hunt Valley
country: United States
state: Maryland
city: Mount Cisco
country: United States
state: New York
Study officials:
affiliation: Medicis Global Pharmaceutical
name: Mary Sanstead
role: STUDY_CHAIR
References: